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 Abstract 
 We compared indices of the revised version of the Wechsler Memory Scale (WMS-R) and scaled 
scores of the five subtests of the revised version of the Wechsler Adult Intelligence Scale (WAIS-
R) in 30 elderly schizophrenia (ES) patients and 25 Alzheimer’s disease (AD) patients in the am-
nestic mild cognitive impairment (aMCI) stage (AD-aMCI). In the WMS-R, attention/concentra-
tion was rated lower and delayed recall was rated higher in ES than in AD-aMCI, although 
general memory was comparable in the two groups. In WAIS-R, digit symbol substitution, sim-
ilarity, picture completion, and block design scores were significantly lower in ES than in AD-
aMCI, but the information scores were comparable between the two groups. Delayed recall and 
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forgetfulness were less impaired, and attention, working memory and executive function were 
more impaired in ES than in AD-aMCI. These results should help clinicians to distinguish ES com-
bined with AD-aMCI from ES alone.    Copyright © 2011 S. Karger AG, Basel 
 Introduction 
  Schizophrenia is a common psychiatric disease with onset usually occurring during 
adolescence or early adulthood. Recently, new atypical antipsychotic drugs for schizophrenia 
have been developed, and social systems to support schizophrenia patients have been estab-
lished. As a result, schizophrenia patients are now living longer than they used to  [1] , and the 
number of elderly schizophrenia (ES) patients is increasing. The number of Alzheimer’s dis-
ease (AD) patients has also increased due to the rapid aging of society. Although the inci-
dence of AD rises with age, AD also occurs in younger patients; the prevalence rate of AD
in people aged   ^  64 years is 0.12 cases per 1,000 people (http://www.mhlw.go.jp/hou-
dou/2009/03/h0319–2.html; Japanese Ministry of Health, Labor and Welfare). Therefore, 
there are many ES patients who also have AD, and their number is supposed to be increas-
ing. In clinical settings, there is a growing need to differentiate between age-related and AD-
related cognitive impairment in patients who have developed schizophrenia in adolescence 
or middle age.
    Because some clinical characteristics of schizophrenia and AD are similar, differentia-
tion between ES and AD can be difficult. Neuropsychiatric symptoms, such as apathy, pov-
erty of speech, and delusional thinking, are common in both types of patients. Neuroimag-
ing studies have shown volume loss in the hippocampus   [2]   and in the frontal lobe   [3]   in 
schizophrenia, and similar losses have been observed in AD   [4]  . Furthermore, patients with 
schizophrenia are impaired in various domains of cognition, such as memory, working 
memory, and executive function  [5] . These symptoms are also observed in patients with AD.
  Acetylcholine esterase inhibitors have been developed for the treatment of AD. Although 
administration of these agents does not result in a radical improvement of symptoms, their 
early administration can improve the prognosis of AD patients  [6] . In addition, disease-mod-
ifying drugs for AD are now being developed. Thus, early diagnosis and early initiation of 
treatment are important in AD patients. One method to identify early AD with a high prob-
ability is the measurement of amnestic mild cognitive impairment (aMCI), which is a syn-
drome characterized by memory performance below the age norm, while intellectual func-
tioning and activities of daily living are otherwise unimpaired   [7]  . A substantial proportion 
of patients with aMCI later develop clinically diagnosable AD  [7] . In order to treat early-stage 
ES patients who have AD in the aMCI stage (AD-aMCI) for AD, it is necessary to differenti-
ate between ES combined with AD, and ES alone. As a first step toward this goal, in this 
study, we clarified the degree of cognitive impairment in patients with ES compared to pa-
tients with AD-aMCI.
  M e t h o d s  
 Subjects 
 All patients in this study were recruited from the Department of Neuropsychiatry of the 
Osaka University Medical Hospital, which includes Schizophrenia and Neuropsychological 
Clinics. At both clinics, patients underwent standard neuropsychological examinations as 
well as routine laboratory tests and cranial magnetic resonance imaging (MRI). Single pho-22
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ton emission computed tomography (SPECT) was performed on patients with aMCI at the 
Neuropsychological Clinic. The clinical and investigative data were collected in a standard-
ized manner and were entered into each registry. In this study, we selected patients with ES 
and patients with AD-aMCI who met the inclusion criteria mentioned below for each group 
from the registry. In the Schizophrenia Clinic, we began using the revised version of the 
Wechsler Adult Intelligence Scale (WAIS-R) in March 2004 and then switched to the third 
version of the WAIS (WAIS-III) in October 2006. In the Neuropsychological Clinic, we be-
gan using five subtests of the WAIS-R in September 2002 and switched to five subtests of the 
WAIS-III in February 2009. In this study, we selected patients who were evaluated with the 
WAIS-R, because few patients with AD-aMCI were evaluated with the WAIS-III and then 
followed up until they reached the dementia stage. The revised version of the Wechsler Mem-
ory Scale (WMS-R) has been used in both clinics as a memory test because the third version 
of the WMS (WMS-III) is not standardized and cannot be used in Japan. In both clinics, the 
WMS-R was usually used before the WAIS-R. However, in some cases, there was no oppor-
tunity to use the WAIS-R.
  ES  Group 
  Thirty patients with schizophrenia (15 women and 15 men) were selected from the 
Schizophrenia Clinic registry. The mean age of the patients was 56.9   8   5.5 years, and the 
mean years of education were 13.2  8   2.3. All subjects in the ES group (1) met the criteria for 
schizophrenia based on the Structured Clinical Interview of the Diagnostic and Statistical 
Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR); (2) were aged   6 50  years 
  [8]  ; (3) showed first symptoms of schizophrenia before 65 years of age; (4) had been evalu-
ated by either the WMS-R or the WAIS-R; (5) had no other neurological disease, and (6) had 
no evidence of focal brain lesions on MRI. Of the 30 patients, 14 were given the WAIS-R 
(group with WAIS-R) and the other 16 were not given the WAIS-R (group without WAIS-R). 
There were no significant differences in gender, age, education, or WMS-R indices between 
the ES groups with and without WAIS-R (  table 1  ). Other demographic data on the ES group 
are summarized in   table 2  . Mean duration of hospitalization was short, although mean du-
ration of disease was long. Many patients received atypical antipsychotic drugs at the time of 
neuropsychological assessment in this study. There were no significant differences between 
the groups with and without WAIS-R in any of the items except for the positive/negative 
symptom scores of the Positive and Negative Syndrome Scale (PANSS). Both PANSS scores 
were higher in the group without WAIS-R than in the group with WAIS-R. Four of the 30 
patients with ES were not given the WMS-R.
Table 1.   Comparison of characteristics of the ES and AD-aMCI groups with and without WAIS-R
Characteristics ES group AD-aMCI group
with WAIS-R without WAIS-R p value with WAIS-R without WAIS-R p value
Sex, male/female 5/9 10/6 0.14 7/6 7/5 0.57
Age, years 56.685.5 57.185.7 0.79 72.686.0 70.289.5 0.44
Education, years 13.182.6 13.382.2 0.79 13.783.3 13.481.8 0.8
MMSE total score – – – 26.181.9 27.082.1 0.27
WMS-R GM index 81.3815.5 79.1817.0 0.75 80.5813.1 74.986.1 0.19
WMS-R AC index 84.8810.3 94.8816.0 0.09 99.8811.1 97.3812.7 0.59
WMS-R DR index 75.9815.9 76.6818.4 0.92 61.589.7 55.886.5 0.123
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  AD-aMCI  Group 
 Twenty-five AD-aMCI patients were selected from the Neuropsychological Clinic regis-
try. The number of males exceeded the number of females (14 males and 11 females). The 
mean age of the patients was 71.4   8   7.8 years, the mean years of education were 13.6   8   2.6, 
and the mean MMSE score was 26.5   8   2.0. All subjects in the AD-aMCI group met the cri-
teria for aMCI, which included (1) a memory complaint documented by the patient or an-
other source; (2) a score in the story A recall task in the logical memory II subtest of WMS-
R which is less than the age-corrected and education-corrected cutoff score; (3) a score of
  6  24 on the MMSE; (4) a total Clinical Dementia Rating (CDR) score of 0.5 and a memory 
CDR score   1  0; (5) normal basic and instrumental activities of daily living evaluated with 
Lawton’s Physical Self-Maintenance Scale and Instrumental Activities of Daily Living Scale 
  [9]  , and (6) no symptoms of dementia based on a clinical examination and an extensive in-
terview with a knowledgeable informant. All subjects in this group also (7) had been evalu-
ated by either the WMS-R or the short form of the Japanese version of the WAIS-R, (8) had 
no other neurological disease, and (9) had no evidence of focal brain lesions on MRI. To con-
firm that the aMCI patients had AD in the preclinical stage, at least one of the following three 
criteria had to be fulfilled: (1) atrophy in the entorhinal cortex on MRI, (2) hypoperfusion in 
the posterior cingulate cortex (PCC) and precuneus on SPECT, or (3) progression to AD dur-
ing annual follow-ups. Progression to AD was defined as meeting the criteria of the Nation-
al Institute of Neurological Disease and Stroke/Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA) for probable AD and a total CDR score of 61.0.
  Progression to AD from aMCI during the subsequent follow-ups (up to 8 years) was con-
firmed in 17 of the 25 patients. Nineteen of the 25 AD-aMCI patients received three-dimen-
sional spoiled gradient echo MRI, which identified atrophy in the entorhinal cortex in 13 of 
the 19 patients. Twenty-three of the 25 AD-aMCI patients received N-isopropyl-p-[  123 I]-io-
doamphetamine (  123  I-IMP)-SPECT, and hypoperfusion in either the PCC or precuneus was 
identified in 12 of the 23 AD-aMCI patients. One patient was recruited due to abnormality 
on the MRI and 7 patients were recruited due to abnormality on SPECT. Of the 25 patients, 
13 were given the five subtests of the WAIS-R (group with WAIS-R) but the other 12 were 
not (group without WAIS-R). There were no significant differences in gender, age, education, 
Table 2.   Characteristics of the ES group
Characteristics ES with WAIS-R
mean8SD
ES without WAIS-R
mean8SD
p 
value
Total
mean8SD (range)
Age of disease onset, years 32.3812.0 30.1812.3 0.64 31.1812.0 (19.0–61.0)
Duration of untreated psychosis, years 3.686.5 4.188.4 0.87 3.987.5 (0–26)
Duration of disease, years 23.8811.7 27.4810.7 0.41 25.8811.1 (1–45)
Total duration of hospitalization, months 14.0812.2 9.7819.6 0.56 11.4816.8 (0–72)
Daily dose of antipsychotic drugs
(chlorpromazine equivalent), mg 554.78283.6 469.18387.6 0.5 509.08340.0 (0.0–1,300.0)
Daily dose of atypical antipsychotic drugs
(chlorpromazine equivalent), mg 485.78306.6 318.88379.9 0.2 396.78352.0 (0.0–1,300.0)
PANSS score
Positive symptoms 12.384.6 16.384.4 0.03 14.584.8 (5–28)
Negative symptoms 12.383.2 18.386.5 0.01 15.586.0 (7–30)
Overall severity in the Drug-Induced Extra-
Pyramidal Symptoms Scale (n = 21) 0.9081.9 0.8680.7 0.94 0.8881.3 (0–6)24
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MMSE score or WMS-R indices between the two groups with and without WAIS-R ( table 1 ). 
All AD-aMCI patients were administered the WMS-R.
    Comparison of Demographic Data in the ES and the AD-aMCI Groups 
  There was no significant difference between the ES and the AD-aMCI groups in terms 
of sex (p = 0.48,     2   test) or education (p = 0.71, t test). However, the ES group was signifi-
cantly younger than the AD-aMCI group (p   !   0.001, t test).
    MRI and SPECT Criteria for the AD-aMCI Group 
 MRI was performed on a 1.5-tesla system (Signa Excite HD 12x; General Electric Medical 
Systems, Milwaukee, Wisc., USA). A three-dimensional volumetric acquisition of a T1-
weighted gradient echo sequence produced a gapless series of thin sagittal sections that cov-
ered the whole calvarium. The operating parameters were as follows: field of view = 240 mm, 
matrix = 256 ! 256, 124 ! 1.40 mm contiguous sections, TR = 12.55 ms, TE = 4.20 ms, and flip 
angle = 15°. The three-dimensional T1-weighted MRI data of the patients were analyzed with 
the voxel-based specific region analysis for AD (VSRAD)   [10]   (  fig. 1  ). VSRAD contained the 
MRI data of normal control subjects with a wide age range and could automatically compare 
the gray matter intensities of the MRI data on a voxel-by-voxel basis between an aMCI patient 
and age-comparable normal control subjects after a series of steps including segmentation, 
anatomical standardization and smoothing using Statistical Parametric Mapping 2002 
(SPM2; Wellcome Department of Imaging Neuroscience, London, UK). The Z-score is calcu-
lated on a voxel-by-voxel basis as (Is – Ic)/SD where Is and Ic are the gray matter intensities of 
an aMCI patient and the mean of normal control subjects, respectively, and SD is the standard 
deviation of the gray matter intensities of the normal control subjects. The region of interest 
was set to the entorhinal cortex in the VSRAD software. Atrophy corresponding to a Z-score 
  1  2.0 in the entorhinal cortex was used as a criterion for AD in the VSRAD method.
  Fig. 1.  Z-score map overlaid on an MRI template of 
a representative patient with AD-aMCI made with 
VSRAD. This patient was included in the study be-
cause of the presence of significant atrophy in the 
entorhinal cortices on MRI. Parts of the colored ar-
eas are in the areas circumscribed by purple lines, 
indicating significant atrophy in the entorhinal 
cortices. Purple lines indicate the bilateral entorhi-
nal cortices. Colored areas on MRI are those with 
a Z-score   1  2 (significant atrophy). Color bar indi-
cates Z-score. 25
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   123 I-IMP-SPECT was performed with a SPECT scanner (SPECT-2000H; Hitachi Medical 
Co., Tokyo, Japan) and a four-head rotating gamma camera. SPECT data were analyzed us-
ing three-dimensional stereotactic surface projection (3D-SSP) software   [11]   (  fig. 2  ). 3D-SSP 
contained   123  I-IMP-SPECT data of normal control subjects with a wide age range and could 
automatically compare the regional cerebral blood flow (rCBF) between an aMCI patient and 
age-comparable normal control subjects. The peak cortical values of the SPECT data were 
projected back and assigned to the original surface images from eight views on a pixel-by-
pixel basis. Z-score was calculated on a pixel-by-pixel basis as (Is – Ic)/SD where Is and Ic are 
the rCBFs of an aMCI patient and the mean of normal control subjects, respectively, and SD 
is the standard deviation of the rCBF of the normal control subjects. Areas with a Z-score 
  1  2.32 (the significance level of the Z-score) were overlaid on original surface images from 
eight views. With the computer program Stereotactic Extraction Estimation (SEE) we deter-
mined which gyri included the regions with a Z-score   1  2.32   [12]  . In SEE, the percentage of 
areas with a Z-score   1  2.32 in each gyrus was calculated and the percentage was called the 
‘extent’. The presence of areas of hypoperfusion, in which both the Z-score was   1 2.32  and 
the extent was   1  10%   [13]   in either the PCC or precuneus, was used as the inclusion criteria 
for AD in the aMCI stage.
    Assessment of Cognitive Functions 
  The attention/concentration (AC) index in the WMS-R was used for measuring atten-
tion and working memory, the general memory (GM) index was used for recent memory, 
and the delayed recall (DR) index for delayed memory. For each index, the normal range is 
  Fig. 2.   Z-score map of a representative patient with AD-aMCI made with 3D-SSP. This patient was in-
cluded in the study because of the presence of hypoperfusion in the PCC and precuneus on SPECT. Col-
ored areas contain PCC and precuneus. Colored areas with significant rCBF reduction with a Z-score of 
  1  2.32 were overlaid on original surface images from eight views. Color bar indicates Z-score. RT.LAT = 
Right lateral; LT.LAT = left lateral; SUP = superior; INF = inferior; ANT = anterior; POST = posterior; 
RT.MED = right medial; LT.MED = left medial. 26
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between 80 and 120 and the mean index of normal subjects is 100. We also defined a new 
index equal to the GM index minus the DR index (GM-DR), which is a measure of the degree 
of forgetfulness.
    For the WAIS-R, five test data were used in this study. Four of the five subtests were in-
formation, digit symbol substitution, similarities, and picture completion, which were se-
lected according to the manual of the short form of the Japanese version of the WAIS-R   [14]  . 
Another was a block design to evaluate visuoconstructive function directly, as this dysfunc-
tion is a common symptom in AD patients. In each age-corrected score of the subtest, the 
normal range is between 7 and 13 and the mean score of normal subjects is 10.
  Statistical  Analyses 
 Age-corrected scores of both the WMS-R and the five subtests of the WAIS-R were com-
pared between the two groups using a t test. The significance level was set at p   !   0.05.
  R e s u l t s  
  Results of the WMS-R 
  In this study, the mean GM indices in the two groups were around the lower limit of the 
normal range, and the mean AC indices in ES and AD-aMCI were normal (  table 3  ). The 
mean DR index of ES was slightly below the normal range, but the mean DR index of AD-
aMCI appeared to be significantly lower. The GM indices of the two groups were compara-
ble. The AC index was significantly lower and the DR index was significantly higher in ES 
than in AD-aMCI. The difference in the GM and DR scores (GM-DR), which is a measure 
of the degree of forgetfulness, was significantly lower in ES than in AD-aMCI.
    Results of the Five Subtests of the WAIS-R 
  The mean scores of all the subtests of the WAIS-R in this study in both groups were 
within the normal range (  table 3  ). The information scores of the two groups were compa-
rable, but scores of the digit symbol substitution, similarity, picture completion, and block 
design subtests were significantly lower in ES than in AD-aMCI.
Table 3.   Cognitive impairment in ES and AD-aMC patients
Test/subtest ES group AD-aMCI group p  value
WMS-R
GM index 80.0816.2 77.8810.5 0.58
AC index 91.0814.7 98.6811.7 0.046
DR index 76.3817.2 58.888.6 <0.001
GM-DR 3.6810.7 19.988.6 <0.001
WAIS-R
Information 10.183.7 11.282.8 0.37
Digit symbol substitution 8.082.7 11.682.3 <0.001
Similarity 9.983.2 12.582.2 0.024
Picture completion 8.584.0 11.281.8 0.037
Block design 8.482.7 11.581.9 0.001827
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  Discussion 
  We could not confirm that all AD-aMCI patients in this study developed AD to the de-
mentia stage. However, we were able to select aMCI patients that had AD-specific findings on 
MRI or SPECT in this study. Pathological abnormalities related to AD, neurofibrillary tangles 
and neuronal loss, were found to be present in the entorhinal cortex of AD in aMCI stage   [15]  , 
leading to atrophy in the region on MRI  [16] . Because the entorhinal cortex is functionally con-
nected to the PCC  [17] , the reduction of rCBF in the PCC was probably caused by the abnormal 
pathology in the entorhinal cortex. In addition, atrophy in the entorhinal cortex on MRI   [18]   
and reduction of rCBF in the PCC and precuneus on SPECT   [19]   predict progression from
MCI to AD. We used two reliable and user-independent statistical image-analyzing methods, 
VSRAD and 3D-SSP, to detect AD-specific abnormalities in the MR and SPECT images.
  This is the first report to compare cognitive impairment between ES and AD-aMCI. The 
WMS-R GM indices of the two groups were comparable, indicating a similarity in the im-
pairment of recent memory between the two groups. Some previous studies compared recent 
memory in ES and AD at the dementia stage. There is some disagreement on whether recent 
memory is better   [20]   or worse   [21]   in ES than in AD in the dementia stage. aMCI is a rela-
tively homogeneous group with respect to memory impairment, because the definition of 
aMCI includes the degree of memory impairment. However, the severity of recent memory 
impairment could vary in patients with ES. The ES patients in this study were mild cases, 
because they could complete the WMS-R or WAIS-R, which are comprehensive tests, and 
the mean duration of their hospitalization was short. Thus, the recent memory tests in this 
study indicated that the recent memory scores of ES patients with mild cognitive impairment 
were comparable with those of AD-aMCI patients, and, therefore, that recent memory was 
not useful for distinguishing between ES and AD-aMCI.
    The fact that the WMS-R GM indices were comparable in the ES and AD-aMCI groups 
indicates that the two groups in this study had similar degrees of impairment of recent mem-
ory. This narrows down the difference between the two groups to differences in other cogni-
tive impairments, such as forgetfulness, and impairments of DR, attention, working memo-
ry and executive function. The WMS-R GM-DR scores were lower and the DR scores were 
higher in ES than in AD-aMCI, indicating that the degree of forgetfulness was less and DR 
was better in ES. On the other hand, the AC was lower in ES than in AD-aMCI, indicating 
that ES patients had more impaired attention and working memory than AD-aMCI patients. 
DR was found to be better in ES patients than in AD patients in the dementia stage   [21]  , and 
forgetfulness did not increase in ES patients but increased in AD patients in the dementia 
stage   [20]  . The present study confirmed that memory after a short while was retained in ES 
but not in AD. In addition, we found that the retention in ES patients was better than in AD 
even at the aMCI stage, which should help to distinguish ES from AD in the very early stage.
    The hippocampus, parahippocampus, and entorhinal cortex have traditionally been 
thought of as the principal structures responsible for the consolidation of short-term stores 
into long-term memory. Significant associations between hippocampal size and memory 
have not been observed in schizophrenia   [22]  , although size reductions in the hippocampus 
have been reported in schizophrenia   [2]  . In addition, memory capabilities were similar to 
general intellectual abilities in ES   [23]  . Therefore, damage in the medial temporal lobe may 
not play an important role in memory impairment in schizophrenia. On the other hand, 
memory impairment in AD is inversely associated with hippocampal volume   [24]  .
    The ES group was more impaired on the digit symbol substitution, similarities, picture 
completion, and block design subtests of WAIS-R than the AD-aMCI group, and each subtest 
score in the ES group was below the mean of each score of the general population in this 
study. Although the block design subtest was used to evaluate visuoconstructive function in 28
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this study, attention and executive function are required to perform the block design subtest 
  [25]  . Thus, these findings confirmed that attention, working memory, and executive func-
tion are impaired in ES. Previous studies reported that ES patients were impaired in the 
WAIS-R digit symbol substitution, similarities, picture completion, and block design sub-
tests   [21]  , and in attention, working memory, and executive function   [20]  . These studies also 
reported that impairment in these functions were comparable in ES and AD patients in the 
dementia stage. The differences in cognitive impairment that we found in ES and AD-aMCI 
deviate from those found in previous studies. This discrepancy may be due to differences in 
the severity of cognitive impairments in the AD-aMCI patients in this study compared to 
the AD patients in the dementia stage in previous studies.
    Which region of the brain is responsible for the difference in attention, working memo-
ry, and executive function in the two groups? Impairments in cognitive function in patients 
with schizophrenia were found to be related to dysfunction of the prefrontal cortex (PFC) 
  [26]  . On the other hand, gray matter loss on MRI   [27]   and pathological abnormality   [28]   in 
the PFC were not observed in AD-aMCI, and gray matter loss on MRI was observed at the 
time of progression from aMCI to AD   [27]  . These results suggest that differences in impair-
ment in attention, working memory, and executive function in the two groups probably re-
flect the difference in impairment in the PFC.
    The WAIS-R information scores of the ES and AD-aMCI groups were comparable and 
within the normal range, being consistent with those of a previous study   [29]  . Semantic 
memory may be preserved in ES and AD-aMCI patients because they have less impairment 
in the inferior and anterior temporal lobe regions, which crucially contribute to semantic 
cognition   [30] .
    There were some limitations in this study. First, approximately half of the patients in 
each group were not given the WAIS-R. Second, the ES patients in this study were younger 
than the AD-aMCI patients, and cognitive function in schizophrenia patients undergoes a 
marked decline after 65 years of age   [8]  . Third, we did not control the effects of medication 
on the cognitive test scores in ES patients. Most ES subjects in this study had received atyp-
ical antipsychotic drugs, which might improve cognitive function   [31]  . These issues should 
be taken into consideration before the findings are generalized.
    In this study, DR and forgetfulness were less impaired in ES than in AD-aMCI, while 
attention, working memory, and executive function were more impaired in ES than in AD-
aMCI. The results of this study should help clinicians to distinguish patients with ES from 
patients with AD-aMCI and might also give us some clues for distinguishing ES combined 
with AD-aMCI from ES alone. The next step is to clarify the difference in the characteristics 
of cognitive impairment in ES combined with AD-aMCI compared to ES alone.
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